β-Lactam Monotherapy vs β-Lactam–Macrolide Combination Treatment in Moderately Severe Community-Acquired Pneumonia
Authors:
- 1 December 2014
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 174 (12) , 1894-901
Abstract
Research from JAMA Internal Medicine — β-Lactam Monotherapy vs β-Lactam–Macrolide Combination Treatment in Moderately Severe Community-Acquired Pneumonia — A Randomized Noninferiority TrialKeywords
This publication has 29 references indexed in Scilit:
- Faculty Opinions recommendation of Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality.2014
- Association of Azithromycin With Mortality and Cardiovascular Events Among Older Patients Hospitalized With PneumoniaJAMA, 2014
- β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysisJournal of Antimicrobial Chemotherapy, 2014
- Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studiesBMJ, 2013
- Azithromycin and the Risk of Cardiovascular DeathNew England Journal of Medicine, 2012
- Guidelines for the management of adult lower respiratory tract infections - Full versionClinical Microbiology and Infection, 2011
- Clinical and economic burden of community-acquired pneumonia among adults in EuropeThorax, 2010
- The need for macrolides in hospitalised community-acquired pneumonia: propensity analysisEuropean Respiratory Journal, 2007
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Predicting Antimicrobial Resistance in Invasive Pneumococcal InfectionsClinical Infectious Diseases, 2005